Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2012 - 2026)

Enanta Pharmaceuticals has reported Cash from Investing Activities for 15 years, with the latest figure at $11.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 373.33% year-over-year to $11.9 million; the trailing twelve-month figure through Mar 2026 stood at -$59.5 million (down 177.07% YoY), and the FY2025 full-year result was $40.3 million, down 30.72% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $11.9 million, up from -$47.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $68.9 million in Q4 2024, with the low at -$145.7 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged $1.1 million across 5 years, with a median of $11.8 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 998.57% — and 2024, when it soared 625.3%.
• Enanta Pharmaceuticals' Cash from Investing Activities stood at $33.6 million in 2022, then plunged by 139.07% to -$13.1 million in 2023, then soared by 625.3% to $68.9 million in 2024, then tumbled by 168.64% to -$47.3 million in 2025, then surged by 125.25% to $11.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $11.9 million (Q1 2026), -$47.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.